Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists (US)

Analysis of: Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II (jco.ascopubs.org)
This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!
Analysis of: Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer (www.pipelinereview.com)
Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???
Analysis of: Studies Find Genetic Link to Smoking (www.nytimes.com)
Gene driven nicotine receptors will predispose to increased smoking. What will this lead to?? Increased addiction due to mutations increases cancer risk.
Analysis of: Pfizer Ends Clinical Trial Of Melanoma Treatment (online.wsj.com)
Drug (monoclonal ab?) failed in a phase III trial vs chemotherapy (not particularly effective.)
Analysis of: Unexpected Toxicity with Panitumumab Plus Chemotherapy-Bevacizumab Combo in Colorectal Cancer (www.oncology-times.com)
Vectibix's undue toxicity without obvious benefits punctures Amgen's hope of finding a first or even second line use for this EGFR directed monoclonal antibody.
Analysis of: OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy (www.pipelinereview.com)
OXiGENE, Inc's., ZYBRESTAT(TM) (fosbretabulin), a vascular disrupting agent (?) is being given with Taxol/Carboplatin (T/C) in a randomized Phase II study. Soooo T/C with or without ZYBRESTAT.
Analysis of: Cancer risk seen with J&J foot gel: FDA (uk.reuters.com)
 "A Johnson & Johnson foot gel used by diabetics may increase the risk of cancer and death, U.S. health officials said on Thursday in announcing an investigation into the issue."
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer (www.pipelinereview.com)
Phase II results ++
Analysis of: Study Ties Belly Fat to Dementia (online.wsj.com)
"Belly Fat" in middle age can be associated with the development of dementia as one ages.
Analysis of: Cigarette Company Paid for Lung Cancer Study (www.nytimes.com)
Support from a cigarette manufacturer raises questions as to the conclusions from this study which says early detection by repetitive CT's can improve cancer cure rates by early detection. (making smoking safer?)

Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next151 to 160 of 714

Analytics


Generated at 2009-01-07T13:00:17.563